دورية أكاديمية
أعرض في EDS

Pancreatic adenocarcinoma and pancreatic high-grade neuroendocrine carcinoma: two sides of the moon.

التفاصيل البيبلوغرافية
العنوان: Pancreatic adenocarcinoma and pancreatic high-grade neuroendocrine carcinoma: two sides of the moon.
المؤلفون: La Salvia A; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy. annalasal@tiscali.it., Persano I; Department of Oncology, San Luigi Gonzaga Hospital, Orbassano, Italy., Parlagreco E; Department of Oncology, San Luigi Gonzaga Hospital, Orbassano, Italy., Audisio A; Department of Oncology, San Luigi Gonzaga Hospital, Orbassano, Italy., Cani M; Department of Oncology, San Luigi Gonzaga Hospital, Orbassano, Italy., Brizzi MP; Department of Oncology, San Luigi Gonzaga Hospital, Orbassano, Italy.
المصدر: Medical oncology (Northwood, London, England) [Med Oncol] 2022 Aug 16; Vol. 39 (11), pp. 168. Date of Electronic Publication: 2022 Aug 16.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2011- : New York : Springer
Original Publication: Northwood, Middlesex, England : Science and Technology Letters, c1994-
مواضيع طبية MeSH: Adenocarcinoma*/diagnosis , Adenocarcinoma*/therapy , Carcinoma, Neuroendocrine*/pathology , Carcinoma, Neuroendocrine*/therapy , Neuroendocrine Tumors*/pathology , Pancreatic Neoplasms*/diagnosis , Pancreatic Neoplasms*/pathology , Pancreatic Neoplasms*/therapy, Humans ; Quality of Life ; Pancreatic Neoplasms
مستخلص: Pancreatic adenocarcinoma is the seventh leading cause of cancer death in the world and the most common type pf pancreatic cancer. Unfortunately, less than 20% of patients are surgically resectable and the great majority of cases are treated with palliative chemotherapy with unsatisfactory results. No targeted agents or personalized approaches have been validated in the last decades. On the other side, neuroendocrine neoplasms of the pancreas are generally considered indolent tumours. However, high-grade neuroendocrine carcinoma is a rare subtype of neuroendocrine neoplasm of the pancreas (accounting up to 10% of the neuroendocrine neoplasms of the pancreas), with particularly aggressive behaviour and poor prognosis. Even in this case, the treatment is represented by palliative chemotherapy with dismal results and no personalized therapies are available, so far. Notably, the quality of life of these patients is disappointingly low and the future perspectives of more personalized diagnostic and therapeutic strategies are scarce. In this review, we discuss relevant and current information on epidemiology, pathology, diagnosis, clinical presentation, treatment and ongoing clinical trials of these two entities, in order to illustrate the two sides of the moon.
(© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
References: Capasso M, Franceschi M, Rodriguez-Castro KI, Crafa P, Cambiè G, Miraglia C, et al. Epidemiology and risk factors of pancreatic cancer. Acta BioMed. 2018;89:141–6. (PMID: 30561407)
Martens S, Lefesvre P, Nicolle R, Biankin AV, Puleo F, Van Laethem JL, et al. Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications. Ann Oncol. 2019;30(9):1428–36. (PMID: 3116120810.1093/annonc/mdz181)
Schlitter AM, Segler A, Steiger K, Michalski CW, Jäger C, Konukiewitz B, et al. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): identification of prognostic subtypes. Sci Rep. 2017;1(7):41064. (PMID: 10.1038/srep41064)
Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):1–18. (PMID: 2134940910.1016/j.ecl.2010.12.005)
Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol. 2011;8(1):54–64. (PMID: 2180829610.1038/nrendo.2011.120)
Păun I, Becheanu G, Costin AI, Constantin VD, Mihai GM, Radu L, et al. Aspects regarding nomenclature, classification and pathology of neuroendocrine neoplasms of the digestive system: a review. Rom J Morphol Embryol. 2018;59(3):673–8. (PMID: 30534804)
Watanabe I, Sasaki S, Konishi M, Nakagohri T, Inoue K, Oda T, et al. Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas. 2004;28(2):160–5. (PMID: 1502894810.1097/00006676-200403000-00007)
Mills K, Birt L, Emery JD, Hall N, Banks J, Johnson M, et al. Understanding symptom appraisal and help-seeking in people with symptoms suggestive of pancreatic cancer: a qualitative study. BMJ Open. 2017;7(9): e015682. (PMID: 28871013558894410.1136/bmjopen-2016-015682)
McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846–61. (PMID: 30487695625092410.3748/wjg.v24.i43.4846)
Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186–94. (PMID: 2673133410.1159/000443172)
Yao W-Q, Wu X, Li G-D, Wu W-L, Wang W-Y. ACTH-secreting pancreatic neuroendocrine carcinoma with ovarian and pelvic metastases causing cushing’s syndrome: a case report. Int J Clin Exp Pathol. 2015;8(11):15396–401. (PMID: 268239014713687)
Pescatori LC, Festa S, Panzuto F, Pilozzi E, Prosperi D, Rinzivillo M, et al. A case of pancreatic small cell neuroendocrine carcinoma associated with SIADH. Pancreas. 2016;45(5):e20-22. (PMID: 2707772010.1097/MPA.0000000000000558)
Ren B, Liu X, Suriawinata AA. Pancreatic ductal adenocarcinoma and its precursor lesions: histopathology, cytopathology, and molecular pathology. Am J Pathol. 2019;189(1):9–21. (PMID: 3055872710.1016/j.ajpath.2018.10.004)
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8. (PMID: 3143351510.1111/his.13975)
Patlas M, Deitel W, Taylor B, Gallinger S, Wilson SR. Focal chronic pancreatitis mimicking pancreatic head carcinoma: are there suggestive features on ultrasound? Can Assoc Radiol J. 2007;58(1):15–21. (PMID: 17408158)
Zhang S, Defrias DVS, Alasadi R, Nayar R. Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA): experience of an academic centre in the USA. Cytopathology. 2010;21(1):35–43. (PMID: 1984314210.1111/j.1365-2303.2009.00664.x)
Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol. 2014;20(24):7864–77. (PMID: 24976723406931410.3748/wjg.v20.i24.7864)
Wartski M, Sauvanet A. 18F-FDG PET/CT in pancreatic adenocarcinoma: a role at initial imaging staging? Diagn Interv Imaging. 2019;100(12):735–41. (PMID: 3140233210.1016/j.diii.2019.07.006)
Wang Z, Chen J-Q, Liu J-L, Qin X-G, Huang Y. FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol. 2013;19(29):4808–17. (PMID: 23922481373285610.3748/wjg.v19.i29.4808)
Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: a European group on tumor markers (EGTM) status report. Ann Oncol. 2010;21(3):441–7. (PMID: 1969005710.1093/annonc/mdp332)
Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266–70. (PMID: 1709784810.1016/j.ejso.2006.10.004)
Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23(7):1713–22. (PMID: 22241899338782410.1093/annonc/mdr561)
Lee DW, Kim MK, Kim HG. Diagnosis of pancreatic neuroendocrine tumors. Clin Endosc. 2017;50(6):537–45. (PMID: 29207856571991910.5946/ce.2017.131)
Kim JH, Eun HW, Kim YJ, Lee JM, Han JK, Choi B-I. Pancreatic neuroendocrine tumour (PNET): staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Eur Radiol. 2016;26(5):1338–47. (PMID: 2625325710.1007/s00330-015-3941-7)
Lee L, Ito T, Jensen RT. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther. 2018;18(9):837–60. (PMID: 29973077628341010.1080/14737140.2018.1496822)
Li J, Lin JP, Shi LH, Wang WJ, Li AQ, Si JM, et al. How reliable is the Ki-67 cytological index in grading pancreatic neuroendocrine tumors? a meta-analysis. J Dig Dis. 2016;17(2):95–103. (PMID: 2671374910.1111/1751-2980.12310)
Jeon SK, Lee JM, Joo I, Lee ES, Park HJ, Jang J-Y, et al. Nonhypervascular pancreatic neuroendocrine tumors: differential diagnosis from pancreatic ductal adenocarcinomas at MR imaging-retrospective cross-sectional study. Radiology. 2017;284(1):77–87. (PMID: 2809249510.1148/radiol.2016160586)
Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16(3):978–85. (PMID: 2010366610.1158/1078-0432.CCR-09-1759)
Korse CM, Taal BG, Vincent A, van Velthuysen M-LF, Baas P, Buning-Kager JCGM, et al. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade A. marker study of chromogranin A, neuron specific enolase, progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer. 2012;48(5):662–71. (PMID: 2194510010.1016/j.ejca.2011.08.012)
Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, et al. The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas. 2017;46(6):707–14. (PMID: 28609356564298510.1097/MPA.0000000000000850)
Jain R, Fischer S, Serra S, Chetty R. The use of cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. Appl Immunohistochem Mol Morphol. 2010;18(1):9–15. (PMID: 1995606410.1097/PAI.0b013e3181ad36ea)
Vilá MR, Balagué C, Real FX. Cytokeratins and mucins as molecular markers of cell differentiation and neoplastic transformation in the exocrine pancreas. Zentralbl Pathol. 1994;140(3):225–35. (PMID: 7524652)
Wang S, You L, Dai M, Zhao Y. Mucins in pancreatic cancer: a well-established but promising family for diagnosis, prognosis and therapy. J Cell Mol Med. 2020;24(18):10279–89. (PMID: 32745356752122110.1111/jcmm.15684)
Nagata K, Horinouchi M, Saitou M, Higashi M, Nomoto M, Goto M, et al. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg. 2007;14(3):243–54. (PMID: 1752019910.1007/s00534-006-1169-2)
Brosens LAA, Hackeng WM, Offerhaus GJ, Hruban RH, Wood LD. Pancreatic adenocarcinoma pathology: changing ‘landscape.’ J Gastrointest Oncol. 2015;6(4):358–74. (PMID: 262617234502163)
Waddell N, Pajic M, Patch A-M, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501. (PMID: 25719666452308210.1038/nature14169)
Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun. 2015;7(6):7686. (PMID: 10.1038/ncomms8686)
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet Lond Engl. 2011;378(9791):607–20. (PMID: 10.1016/S0140-6736(10)62307-0)
Xu Z, Pothula SP, Wilson JS, Apte MV. Pancreatic cancer and its stroma: a conspiracy theory. World J Gastroenterol. 2014;20(32):11216–29. (PMID: 25170206414576010.3748/wjg.v20.i32.11216)
Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SGH, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168–78. (PMID: 26343385491205810.1038/ng.3398)
Jang J-E, Hajdu CH, Liot C, Miller G, Dustin ML, Bar-Sagi D. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep. 2017;20(3):558–71. (PMID: 28723561564937410.1016/j.celrep.2017.06.062)
Guilmette JM, Nosé V. Neoplasms of the neuroendocrine pancreas: an update in the classification, definition, and molecular genetic advances. Adv Anat Pathol. 2019;26(1):13–30. (PMID: 2991200010.1097/PAP.0000000000000201)
Scoazec J-Y, Couvelard A. Réseau tenpath classification of pancreatic neuroendocrine tumours: changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future. Ann Pathol. 2017;37(6):444–56. (PMID: 2916983610.1016/j.annpat.2017.10.003)
Basturk O, Tang L, Hruban RH, Adsay V, Yang Z, Krasinskas AM, et al. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol. 2014;38(4):437–47. (PMID: 24503751397700010.1097/PAS.0000000000000169)
Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40(9):1192–202. (PMID: 27259015498812910.1097/PAS.0000000000000662)
Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36(2):173–84. (PMID: 22251937326142710.1097/PAS.0b013e3182417d36)
Chai SM, Brown IS, Kumarasinghe MP. Gastroenteropancreatic neuroendocrine neoplasms: selected pathology review and molecular updates. Histopathology. 2018;72(1):153–67. (PMID: 2923903810.1111/his.13367)
Tang LH, Untch BR, Reidy DL, O’Reilly E, Dhall D, Jih L, et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res. 2016;22(4):1011–7. (PMID: 2648204410.1158/1078-0432.CCR-15-0548)
Delpero JR, Boher JM, Sauvanet A, Le Treut YP, Sa-Cunha A, Mabrut JY, et al. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? a survey of the association française de chirurgie. Ann Surg Oncol. 2015;22(6):1874–83. (PMID: 2566594710.1245/s10434-014-4304-3)
Tol JAMG, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the international study group on pancreatic surgery (ISGPS). Surgery. 2014;156(3):591–600. (PMID: 2506100310.1016/j.surg.2014.06.016)
Croome KP, Farnell MB, Que FG, Reid-Lombardo KM, Truty MJ, Nagorney DM, et al. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? Ann Surg. 2014;260(4):633–8. (PMID: 2520388010.1097/SLA.0000000000000937)
Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet Lond Engl. 2001;358(9293):1576–85. (PMID: 10.1016/S0140-6736(01)06651-X)
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77. (PMID: 1722797810.1001/jama.297.3.267)
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81. (PMID: 2082343310.1001/jama.2010.1275)
Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet Lond Engl. 2017;389(10073):1011–24. (PMID: 10.1016/S0140-6736(16)32409-6)
Margaret AT, Michele R, Hanno R, et al. APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. J Clin Oncol. 2019;37:4000–4000. (PMID: 10.1200/JCO.2019.37.15_suppl.4000)
Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020;5(3):285–94. (PMID: 3195307910.1016/S2468-1253(19)30327-9)
Pascal H, Florence H, Van Jean-Luc L, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. J Clin Oncol. 2013;31:LBA4003–4. (PMID: 10.1200/jco.2013.31.18_suppl.lba4003)
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. (PMID: 2156134710.1056/NEJMoa1011923)
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. (PMID: 10.1056/NEJMoa1304369)
Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):413–23. (PMID: 2962584110.1016/S2468-1253(18)30081-5)
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–13. (PMID: 919615610.1200/JCO.1997.15.6.2403)
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–27. (PMID: 31157963681060510.1056/NEJMoa1903387)
Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet Lond Engl. 2016;387(10018):545–57. (PMID: 10.1016/S0140-6736(15)00986-1)
Partelli S, Cirocchi R, Rancoita PMV, Muffatti F, Andreasi V, Crippa S, et al. A systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. HPB. 2018;20(3):197–203. (PMID: 2919602210.1016/j.hpb.2017.10.014)
Panzuto F, Rinzivillo M, Spada F, Antonuzzo L, Ibrahim T, Campana D, et al. Everolimus in pancreatic neuroendocrine carcinomas G3. Pancreas. 2017;46(3):302–5. (PMID: 2809925410.1097/MPA.0000000000000762)
Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–13. (PMID: 2130623710.1056/NEJMoa1003825)
Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–60. (PMID: 2296799410.1093/annonc/mds276)
Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60. (PMID: 3227220810.1016/j.annonc.2020.03.304)
Frizziero M, Spada F, Lamarca A, Kordatou Z, Barriuso J, Nuttall C, et al. Carboplatin in combination with oral or intravenous etoposide for extra-pulmonary. Poorly-Differ Neuroendocr Carcinomas Neuroendocrinol. 2019;109(2):100–12.
Kobayashi N, Takeda Y, Okubo N, Suzuki A, Tokuhisa M, Hiroshima Y, et al. Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma. Cancer Sci. 2021;112(5):1936–42. (PMID: 33453146808894410.1111/cas.14811)
Bongiovanni A, Liverani C, Pusceddu S, Leo S, Di Meglio G, Tamberi S, et al. Randomised phase II trial of CAPTEM or FOLFIRI as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol. BMJ Open. 2020;10(7): e034393. (PMID: 32690499737123610.1136/bmjopen-2019-034393)
Craig Z, Swain J, Batman E, Wadsley J, Reed N, Faluyi O, et al. NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open. 2020;10(2): e034527. (PMID: 32029495704524010.1136/bmjopen-2019-034527)
Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of (177Lu-DOTA0, Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617–24. (PMID: 2842819210.1158/1078-0432.CCR-16-2743)
Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer. 2019;26(2):227–39. (PMID: 3054055710.1530/ERC-18-0424)
Rishi A, Goggins M, Wood LD, Hruban RH. Pathological and molecular evaluation of pancreatic neoplasms. Semin Oncol. 2015;42(1):28–39. (PMID: 2572605010.1053/j.seminoncol.2014.12.004)
Goral V. Pancreatic cancer: pathogenesis and diagnosis. Asian Pac J Cancer Prev. 2015;16(14):5619–24. (PMID: 2632042610.7314/APJCP.2015.16.14.5619)
Torres C, Grippo PJ. Pancreatic cancer subtypes: a roadmap for precision medicine. Ann Med. 2018;50(4):277–87. (PMID: 2953730910.1080/07853890.2018.1453168)
Cros J, Raffenne J, Couvelard A, Poté N. Tumor heterogeneity in pancreatic adenocarcinoma. Pathobiol J Immunopathol Mol Cell Biol. 2018;85(1–2):64–71. (PMID: 10.1159/000477773)
Zhu H, Li T, Du Y, Li M. Pancreatic cancer: challenges and opportunities. BMC Med. 2018;16(1):214. (PMID: 30463539624972810.1186/s12916-018-1215-3)
Bauer MR, Bright EE, MacDonald JJ, Cleary EH, Hines OJ, Stanton AL. Quality of life in patients with pancreatic cancer and their caregivers: a systematic review. Pancreas. 2018;47(4):368–75. (PMID: 2952193910.1097/MPA.0000000000001025)
Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020;70(5):375–403. (PMID: 32683683772200210.3322/caac.21626)
Wilkowski R, Wolf M, Heinemann V. Primary advanced unresectable pancreatic cancer. Recent Results Cancer Res. 2008;177:79–93. (PMID: 1808495010.1007/978-3-540-71279-4_10)
Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, et al. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016;12(16):1929–46. (PMID: 2724662810.2217/fon-2016-0010)
Lu L, Shang Y, Mullins CS, Zhang X, Linnebacher M. Epidemiologic trends and prognostic risk factors of patients with pancreatic neuroendocrine neoplasms in the US: an updated population-based study. Future Oncol. 2021;17(5):549–63. (PMID: 3340195810.2217/fon-2020-0543)
Young K, Starling N, Sadanandam A. The molecular biology of pancreatic neuroendocrine neoplasms: challenges and translational opportunities. Semin Cancer Biol. 2020;61:132–8. (PMID: 3157796110.1016/j.semcancer.2019.09.024)
Yan J, Yu S, Jia C, Li M, Chen J. Molecular subtyping in pancreatic neuroendocrine neoplasms: new insights into clinical, pathological unmet needs and challenges. Biochim Biophys Acta Rev Cancer. 2020;1874(1): 188367. (PMID: 3233960910.1016/j.bbcan.2020.188367)
Wang H, Lin Z, Li G, Zhang D, Yu D, Lin Q, et al. Validation and modification of staging systems for poorly differentiated pancreatic neuroendocrine carcinoma. BMC Cancer. 2020;20(1):188. (PMID: 32138704705932510.1186/s12885-020-6634-9)
Muscogiuri G, Altieri B, Albertelli M, Dotto A, Modica R, Barrea L, Fanciulli G, Feola T, Baldelli R, Ruggeri RM, Gallo M, Guarnotta V, Malandrino P, Messina E, Venneri MA, Giannetta E, Ferone D, Colao A, Faggiano ANIKE. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine. 2020;69(2):441–50. https://doi.org/10.1007/s12020-020-02331-3 . (PMID: 10.1007/s12020-020-02331-332468269)
Bongiovanni A, Liverani C, Foca F, Fausti V, Di Menna G, Mercatali L, et al. Temozolomide alone or combined with capecitabine for the treatment of metastatic neuroendocrine neoplasia: a ‘real-world’ data analysis. Neuroendocrinology. 2021;111(9):895–906. (PMID: 3322180610.1159/000513218)
فهرسة مساهمة: Keywords: Evidences; Future perspectives; Pancreatic adenocarcinoma; Pancreatic cancer; Pancreatic neuroendocrine carcinoma
تواريخ الأحداث: Date Created: 20220816 Date Completed: 20220818 Latest Revision: 20231213
رمز التحديث: 20231215
DOI: 10.1007/s12032-022-01764-2
PMID: 35972607
قاعدة البيانات: MEDLINE
الوصف
تدمد:1559-131X
DOI:10.1007/s12032-022-01764-2